Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition

Project description

Targeted therapy for watery diarrhoea

Although many cases of acute watery diarrhoea are caused by bacteria, the World Health Organization advises against routine antibiotic use. The EU-funded TARGET project will conduct a clinical trial in Kenya and Tanzania to assess whether targeted antibiotic treatment improves outcomes, identify children most likely to benefit, and evaluate risks including antimicrobial resistance. Findings will inform WHO guidelines and policies for diarrhoea management. By improving care for vulnerable children, TARGET aims to reduce morbidity, mortality, and repeat hospitalisations, including during future climate challenges. The overall goal is to improve diarrhoea management.

Objective

BACKGROUND: Diarrhoea is an important cause of morbidity and mortality in children under 5, especially in SSA. WHO guidelines do not recommend antibiotics for acute watery diarrhoea, while 25-50% of watery diarrhoea episodes are caused by bacteria. Children with co-morbid malnutrition and watery diarrhoea are more likely to have bacterial aetiology and poor outcomes. We hypothesize that the benefits of appropriate antibiotic treatment for these children are greater than the associated risks.
AIM: TARGET aims to generate evidence on how improved management and treatment of watery diarrhoea in children with malnutrition can reduce childhood morbidity and mortality, and support implementation of this evidence across SSA, now and in a climate-uncertain future.
APPROACH: Central to our approach is a clinical trial evaluating the benefit of two antibiotic treatments for watery diarrhoea in children with malnutrition in Kenya and Tanzania. We will assess the characteristics of children who most benefit from therapy and estimate generalizability of the observed effects to other vulnerable populations and under future climate scenarios. We will evaluate the risk-benefit trade-off with the development of antimicrobial resistance and assess provider perspectives on antibiotic use and clinical guidelines. In our dissemination, we focus on uptake in WHO guidelines and policy translation. A critical focus of the project is the development of capacity for leadership of multisite clinical trials focused on enteric infections at KEMRI (Kenya) and HGHRI (Tanzania).
IMPACT: Our late-stage clinical data will directly inform guidelines for treating children with watery diarrhoea and malnutrition and contribute to timely identification of vulnerable children. This has potential to reduce childhood deaths and repeat hospitalization. Importantly, TARGET will contribute to leadership of our SSA partners in future clinical trials, funding applications, impactful research, and publications.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2025-04-two-stage

See all projects funded under this call

Coordinator

STICHTING AMSTERDAM UMC
Net EU contribution
€ 1 812 485,00
Total cost
€ 1 812 485,00

Participants (5)

Partners (3)